
Opinion|Videos|November 11, 2024
Potential Synergies With T-Cell Engagers
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease factors (eg, tumor expression profiles and previous treatment responses) could influence the decision to pursue dual T-cell engager therapy in early clinical development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
In your opinion, what treatment synergies might you expect from a combination of MK-6070, the trispecific T-cell engager, and ifinatamab deruxtecan?
• At this stage in early clinical development, which patient and/or disease factors might persuade you to consider dual T-cell engager therapy?
Advertisement
Related to this article

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
